



**FOR IMMEDIATE RELEASE**

**For Further Information:**  
Rick Carlson  
Chief Executive Officer  
(952) 476-9093  
rcarlson@prourocare.com

## **ProUroCare Medical to Showcase Innovative Prostate Imaging Device at 2009 AUA Annual Scientific Meeting**

EDEN PRAIRIE, MN, April 15, 2009 – ProUroCare Medical Inc. (**OTCBB: PUMD**), announced today it will be attending the American Urological Association (AUA) Annual Scientific Meeting in Chicago, IL, being held April 25-30, 2009, at McCormick Place, and will exhibit in Booth # 1233.

ProUroCare plans to showcase its ProUroScan system, a patented-imaging system designed to provide a map of the prostate and to store a digital image for review. As an adjunctive tool to a digital rectal exam (DRE), this first generation system aids the physician in visualizing and documenting abnormalities in the prostate previously detected by a DRE. The data acquired allows the calculation of prostate features such as size and shape. In addition to the real-time visual image, the results are stored electronically, allowing for comparison of the abnormality's changes over time.

“We look forward to this opportunity to highlight our ProUroScan system and its significant capabilities for urologists and healthcare professionals at the AUA Annual Meeting,” stated Rick Carlson, ProUroCare’s Chief Executive Officer. “We believe the ProUroScan system, when used for basic mapping and data maintenance will be regulated as a Class II device and cleared through a 510(k) application. Our protocol calls for a 40-patient clinical trial involving participation by four different physicians. In addition to the recently completed initial study, a second physician has nearly completed his patient trials, and two more are expected to begin their studies in the near future,” concluded Mr. Carlson.

The AUA Annual Scientific Meeting is the largest meeting of urologic professionals in the world and is attended by more than 10,000 urologists and healthcare professionals. This year, more than 2,000 abstracts will be presented and more than 300 exhibitors will showcase their products and services in the Science and Technology Hall.

### **About ProUroCare Medical Inc.**

ProUroCare Medical Inc. is developing innovative products for the detection and characterization of urological prostate disease. Currently, the Company’s primary focus is the ProUroScan prostate imaging system, which is now in clinical trials. The ProUroCare system is currently available for investigational use only.

### **About the American Urological Association**

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 16,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients.

### ***Safe Harbor Statement***

*This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-KSB and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.*